Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.55 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480358 | 0.88 | RAB9A (0.71) | NPC1RAB9AERCC1ERCC4LMNA | |
| SCHEMBL6480854 | 0.87 | ERCC1 (0.72) | NPC1RAB9AERCC1ERCC4CNR1 | |
| SCHEMBL6479194 | 0.80 | MEN1 (0.55) | RAB9AERCC1ERCC4LMNASMN1; SMN2 | |
| SCHEMBL6479657 | 0.78 | EPHX2 (0.60) | NPC1RAB9AERCC1ERCC4SMN1; SMN2 | |
| SCHEMBL26378655 | 0.76 | SMN1; SMN2 (0.57) | LMNASMN1; SMN2HTT | |
| SCHEMBL6101644 | 0.76 | SMN1; SMN2 (0.64) | LMNASMN1; SMN2HTT | |
| SCHEMBL6479804 | 0.76 | MEN1 (0.58) | RAB9AERCC1ERCC4LMNASMN1; SMN2 | |
| SCHEMBL29615111 | 0.76 | CNR1 (0.82) | SMN1; SMN2CNR1HTT | |
| SCHEMBL22834264 | 0.76 | CNR1 (0.82) | SMN1; SMN2CNR1HTT | |
| SCHEMBL6481200 | 0.75 | CA1 (0.63) | ERCC1ERCC4LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154230-A1 | Urea derivatives | BAYER HEALTHCARE AG (DE) | 2005-07-14 | — | — | US | claimed |
| US-20050154230-A1 | Urea derivatives | BAYER HEALTHCARE AG (DE) | 2005-07-14 | — | — | US | disclosed |
| EP-1461311-A2 | UREA DERIVATIVES AS VR1-ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003055848-A2 | UREA DERIVATIVES AS VR1- ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154230-A1 | Urea derivatives | SLC14A1, UBA1, VAT1 | NPC1 2328/4885RAB9A 1434/4885ERCC1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.